4E Therapeutics
Delivering innovative medicines for pain
4etherapeutics.com|Craig Benson|cbenson@4etherapeutics.com | 512-626-2770

COMPANY OVERVIEW

4E Therapeutics, founded in Austin, TX in 2019, is developing small molecule MNK inhibitors for treating multiple types of pain. 4E compounds selectively target MNK in the periphery to interrupt a key pathway involved in pain signaling. Our drug candidates are peripherally restricted and free of CNS side effects.

4ET1103 is our lead asset for pain with potential indications including neuropathic pain, low back pain, osteo & rheumatoid arthritis (RA) pain and migraine. The candidate has completed IND-enabling studies and will start phase 1 clinical trials in early 2025. 4ET1103 is on track to become a first-in-class pain medication.

4ET2124 and ***4ET2104*** are clinical candidates being developed for additional pain indications or RA (disease itself). They have completed preliminary *in vitro* safety studies and are ready to begin IND-enabling studies.

MARKET & COMMERCIALIZATION STRATEGY

Over 20M Americans suffer from neuropathic pain. We see a $10B annual market revenue opportunity for a novel neuropathic pain therapeutic that excludes side effects associated with opioids.

TECHNICAL & COMPETITIVE ADVANTAGE

Mitogen-activated protein kinase interacting kinase (MNK) regulates changes in gene expression critical for pain and inflammation. Inhibiting MNK interrupts pathways involved in neuropathic pain and migraine—all independent of the opioid pathway. 4E compounds are efficacious in both rodent pain models and human DRG neurons. 4E drug candidates have excellent safety profiles and lack CNS side effects, offering a significant advantage over standard of care medications.

REGULATORY STRATEGY & INTELLECTUAL PROPERTY

4E has an extensive IP portfolio covering 4ET1103, 4ET2124, 4ET2104 and related molecules. A prior art search and analysis verifying strong patent position for clinical candidates has been provided by patent counsel.

KEY MILESTONES

☑ *In vivo* tox studies of 4ET1103
☑ IND application for 4ET1103 submitted
☐ First-in-human phase 1 trial of 4ET1103 to start Q1'25

CAPITALIZATION HISTORY

YEAR	FUNDING TYPE	DESCRIPTION	AMOUNT
2019-23	NIH Grants	Non-dilutive SBIR funding	$7.5M
2021-24	Private	Other	Undisclosed
2025	NIH Grants	Non-dilutive SBIR funding	Undisclosed

USE OF PROCEEDS

Funds will enable completion of phase I clinical trial with 4ET1103

MANAGEMENT TEAM

Craig Benson, CEO
Theodore "Ted" Price, PhD., Co-Founder, Professor at University of Texas at Dallas
James Sahn, PhD., Vice President of Drug Development
Michele Curatolo, MD. PhD., Chief Medical Officer
Joseph "Joe" Price, JD, Co-Founder, President & Chairman